Mangiferin induces apoptosis in multiple myeloma cell lines by suppressing the activation of nuclear factor kappa B-inducing kinase.

[1]  S. Kanekar,et al.  Imaging of Multiple Myeloma. , 2016, Hematology/oncology clinics of North America.

[2]  T. Takeda,et al.  Overexpression of survivin via activation of ERK1/2, Akt, and NF-κB plays a central role in vincristine resistance in multiple myeloma cells. , 2015, Leukemia research.

[3]  I. Nishigaki,et al.  Mangiferin in cancer chemoprevention and treatment: pharmacokinetics and molecular targets , 2015, Journal of receptor and signal transduction research.

[4]  T. Takeda,et al.  Dimethyl fumarate induces apoptosis of hematopoietic tumor cells via inhibition of NF-κB nuclear translocation and down-regulation of Bcl-xL and XIAP. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[5]  T. Derlin,et al.  Imaging of multiple myeloma: Current concepts. , 2014, World journal of orthopedics.

[6]  T. Takeda,et al.  Inhibition of the tumour necrosis factor-alpha autocrine loop enhances the sensitivity of multiple myeloma cells to anticancer drugs. , 2013, European journal of cancer.

[7]  Wei Cheng,et al.  Mangiferin exerts antitumor activity in breast cancer cells by regulating matrix metalloproteinases, epithelial to mesenchymal transition, and β-catenin signaling pathway. , 2013, Toxicology and applied pharmacology.

[8]  M. Imano,et al.  Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells. , 2012, Leukemia research.

[9]  J. Laubach,et al.  Lenalidomide for the treatment of relapsed and refractory multiple myeloma , 2012, Cancer management and research.

[10]  Michele Cavo,et al.  Proteasome inhibitors in multiple myeloma: 10 years later. , 2012, Blood.

[11]  G. Sethi,et al.  Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: potential role in prevention and therapy of cancer. , 2012, Cancer letters.

[12]  A. Taga,et al.  Mangiferin induces apoptosis by suppressing Bcl-xL and XIAP expressions and nuclear entry of NF-κB in HL-60 cells , 2011, Archives of pharmacal research.

[13]  J. Keats,et al.  Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. , 2010, Blood.

[14]  R. Xu,et al.  Berbamine, a novel nuclear factor κB inhibitor, inhibits growth and induces apoptosis in human myeloma cells , 2009, Acta Pharmacologica Sinica.

[15]  R. Kyle,et al.  Treatment of multiple myeloma: a comprehensive review. , 2009, Clinical lymphoma & myeloma.

[16]  E Terpos,et al.  International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma , 2009, Leukemia.

[17]  M. Karin,et al.  Regulation and function of NF-kappaB transcription factors in the immune system. , 2009, Annual review of immunology.

[18]  R. Bataille,et al.  Impact of XIAP protein levels on the survival of myeloma cells , 2009, Haematologica.

[19]  KyungMann Kim,et al.  Bortezomib-Resistant Nuclear Factor-κB Activity in Multiple Myeloma Cells , 2008, Molecular Cancer Research.

[20]  R. Youle,et al.  Mitochondrial dynamics and apoptosis. , 2008, Genes & development.

[21]  G. Cheng,et al.  Control of canonical NF-κB activation through the NIK–IKK complex pathway , 2008, Proceedings of the National Academy of Sciences.

[22]  S. Singhal,et al.  Lenalidomide in Myeloma , 2007, Current treatment options in oncology.

[23]  L. Staudt,et al.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. , 2007, Cancer cell.

[24]  M. Karin.  Nuclear factor-κB in cancer development and progression , 2006, Nature.

[25]  Zhijian J. Chen.  Ubiquitin signalling in the NF-κB pathway , 2005, Nature Cell Biology.

[26]  P. Ramakrishnan,et al.  Receptor-Specific Signaling for Both the Alternative and the Canonical NF-κB Activation Pathways by NF-κB-Inducing Kinase , 2004 .

[27]  Byung Hak Kim,et al.  Inhibitory action of novel aromatic diamine compound on lipopolysaccharide‐induced nuclear translocation of NF‐κB without affecting IκB degradation , 2004 .

[28]  G. Ghosh,et al.  Discreet mutations from c-Rel to v-Rel alter κB DNA recognition, IκBα binding, and dimerization: implications for v-Rel oncogenicity , 2004, Oncogene.

[29]  A. Goldberg,et al.  Protein degradation and protection against misfolded or damaged proteins , 2003, Nature.

[30]  F. Ubeira,et al.  Mangifera indica L. extract (Vimang) and mangiferin modulate mouse humoral immune responses , 2003, Phytotherapy research : PTR.

[31]  Cagla Akay Yair Gazitt.  Arsenic Trioxide Selectively Induces Early and Extensive Apoptosis via the APO2/Caspase-8 Pathway Engaging the Mitochondrial Pathway in Myeloma Cells with Mutant p53 , 2003, Cell cycle.

[32]  I. A. Ross,et al.  Mangifera indica L. , 2003 .

[33]  N. Munshi,et al.  NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.

[34]  M. Karin,et al.  Missing Pieces in the NF-κB Puzzle , 2002, Cell.

[35]  S. Alkan,et al.  Analysis of expression of nuclear factor κB (NF‐κB) in multiple myeloma: downregulation of NF‐κB induces apoptosis , 2001 .

[36]  A I Pick,et al.  THE TREATMENT OF MULTIPLE MYELOMA , 1948, Harefuah.

[37]  T. Takeda,et al.  By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells. , 2014, Leukemia research.

[38]  M. van de Venter,et al.  Combination treatment with oxaliplatin and mangiferin causes increased apoptosis and downregulation of NFκB in cancer cell lines. , 2011, African journal of traditional, complementary, and alternative medicines : AJTCAM.

[39]  M. Venter,et al.  COMBINATION TREATMENT WITH OXALIPLATIN AND MANGIFERIN CAUSES INCREASED APOPTOSIS AND DOWNREGULATION OF NFΚB IN CANCER CELL LINES , 2011 .

[40]  Zhijian J. Chen.  Ubiquitin signalling in the NF-kappaB pathway. , 2005, Nature cell biology.

[41]  Byung Hak Kim,et al.  Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-kappaB without affecting IkappaB degradation. , 2004, FEBS letters.

[42]  P. Ramakrishnan,et al.  Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase. , 2004, Immunity.

[43]  G. Ghosh,et al.  Discreet mutations from c-Rel to v-Rel alter kappaB DNA recognition, IkappaBalpha binding, and dimerization: implications for v-Rel oncogenicity. , 2004, Oncogene.

[44]  S. Alkan,et al.  Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. , 2001, British journal of haematology.

[45]  M J May,et al.  NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. , 1998, Annual review of immunology.

[46]  B. Quesnel,et al.  p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. , 1994, Blood.